sensor receptor [8, 9]; also, the poor response to calcitriol Calcitriol is currently used to reduce parathyroid hormone
treatment is associated with factors such as the failure (PTH) levels in uremic patients. However, a significant number to control the serum phosphorus [2, 10, 11] . This review of patients fail to respond to calcitriol therapy. The data suggest will analyze the characteristics and factors involved in that a poor response to calcitriol can be anticipated in patients the pathogenesis of refractory hyperparathyroidism.
with severe hyperparathyroidism (with a high basal PTH levels) and uncontrolled serum phosphate. The abnormal parathyroid response to calcitriol in uremic patients with severe parathyroid hyperplasia may be attributed, to a large extent, to the develop- In a recent study [12] we analyzed parathyroid funcin the development of polyclonal parathyroid hyperplasia, at earlier stages of secondary hyperparathyroidism, appear to be tion (PTH-Ca curve) in 50 hemodialysis patients with the same factors that stimulate PTH secretion and synthesis: PTH greater than 300 before and after 3 months of bolus hypocalcemia, hyperphosphatemia and low serum calcitriol calcitriol therapy (3-6 g). Patients were divided into levels. Studies performed in vitro using parathyroid tissue from responders and non-responders based on whether the uremic patients who required parathyroidectomy demonstrate predialysis PTH value decreased by 40% or more in that in nodular hyperplasia there is an abnormal response to calcium and calcitriol, which suggests that there are factors response to CTR treatment; this value was selected beintrinsic to the hyperplastic cell (such as decrease in calcium cause it represented the median for the total group of sensor receptors and vitamin D receptors) responsible for an 50 patients. Before initiation of treatment, the mean abnormal regulation of parathyroid function. Accumulation of basal PTH, maximal PTH, and minimal PTH were phosphate is a key factor in the pathogenesis of secondary hyperparathyroidism and a poor response to calcitriol treat-greater in non-responders than responders. Serum calment is associated with the failure to control the serum phoscium concentration was similar in both groups and the phorus. High phosphate stimulates PTH secretion as demonserum phosphate was greater in non-responders than strated by in vivo and in vitro studies. In addition, animal responders. The data suggest that a poor response to studies strongly suggest that phosphate increases parathyroid calcitriol can be anticipated in patients with severe hycell proliferation. There are growth-related genes potentially involved in uremic hyperparathyroidism; however, changes in perparathyroidism and uncontrolled serum phosphate.
ABNORMAL PARATHYROID FUNCTION IN
the expression of these genes may be the consequence rather
The probability of a response to CTR based on pre-CTR than the cause of parathyroid hyperplasia.
basal PTH values is shown for the model in Figure 1 . A 50% probability of a response (40% reduction in basal PTH) was observed at a pre-CTR basal PTH value of 750 Calcitriol is currently used to reduce parathyroid horpg/mL. At a basal PTH of 1200 pg/mL, the probability of mone (PTH) levels in uremic patients [1], however, a a response to CTR was less than 20% and at a basal significant number of patients fail to respond to calcitriol PTH of 400 pg/mL, the probability of a response aptherapy [2-4]. These failures have been ascribed to inproached 80%. trinsic factors associated with large, hyperplastic para-One of the parameters analyzed in this study was the thyroid glands such as nodular hyperplasia [5-7] with ratio of basal to maximal PTH (basal PTH divided by decreased levels of vitamin D receptor [7] and calcium the maximal PTH; this fraction was multiplied by 100), which in normal volunteers is 20% to 25% [13]. By correcting the actual PTH for the overall capacity to produce
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be attributed, to a large extent, to the development of nodular hyperplasia as a result of clonal transformation from a diffuse hyperplasia [15, 16] . Different research groups have reported that in nodular areas there is a decrease in calcium sensor receptor expression [8, 9] , which may explain the abnormal response of these parathyroid glands to the increase in calcium induced by calcitriol administration. Calcitriol acts on parathyroid glands independently of calcium, however, the decrease in vitamin D receptor density also observed in nodular hyperplasia [7] may explain the refractoriness to calcitriol treatment. Studies performed in vitro using parathy- At a basal PTH of 1200 pg/mL, the probability of a response to calcitriol was less than 20%, and at a basal PTH of 400 pg/mL, the probability vitamin D receptors) that are responsible for an abnorof a response approached 80%.
mal regulation of parathyroid function. We have evaluated the ability of calcium to reduce PTH secretion in vitro in parathyroid tissue from uremic patients that required parathyroidectomy [18] . As shown in Figure 3 , is low, the basal to maximal PTH ratio should be high, the degree of inhibition of PTH secretion by calcium indicating that the parathyroid gland is using more of its was greater in diffuse than nodular hyperplasia; in primary overall capacity to correct the low calcium; conversely, parathyroid hyperplasia very high calcium concentrations an increase of calcium must decrease basal PTH relative were necessary to produce a significant decrease in PTH to maximal PTH. Figure 2 shows the changes in basal/ secretion. In a different study we evaluated in vitro, the maximal PTH ratio produced by calcitriol treatment in effect of calcitriol on parathyroid cell cycle and apoptosis responders and non-responders. The basal/maximal PTH in parathyroid glands from patients with severe hyperratio, which reflects the relative degree of parathyroid parathyroidism [19] . In these glands, parathyroid cell progland sensitivity to the serum calcium, decreased in the liferation was not inhibited by concentrations of calcitriol responders group from 52 Ϯ 3% to 33 Ϯ 3% (P Ͻ 0.001) ranging from 10 Ϫ10 to 10 Ϫ8 mol/L; a moderate decrease after CTR treatment as the serum calcium concentration in proliferation was observed when calcitriol concentraincreased ( Fig. 2A ). Conversely, in the non-responders tion in the medium reached 10 Ϫ7 mol/L ( Fig. 4 ). In this group, the basal/maximal PTH ratio did not change destudy, it was observed that a high concentration of spite the increase in serum calcium and a similar shift calcitriol produced a decrease in the number of apoptotic to the right of the PTH-calcium curve (Fig. 2B ). The cells that was parallel to the decrease in proliferation. magnitude of the absolute reduction in PTH in the re-Because calcitriol simultaneously inhibits cell proliferasponder group (Fig. 2C ) and the lack of a change in the tion and apoptosis, a reduction in the parathyroid gland non responder group (Fig. 2D ) can be appreciated in mass may not occur as a direct effect of calcitriol treatthe PTH-calcium curves shown in these figures.
ment. The PTH response to calcitriol was also affected by high serum phosphate. In both groups, responders and NODULAR HYPERPLASIA non responders, patients with serum phosphate greater than 6 mg/dL showed less reduction in PTH than those
The reason for the high frequency of clonal proliferawith serum phosphate below 6 mg/dL. tion is unclear. Probably the long-standing stimulation The set point was not different in responders and non of a tissue with a usually extremely slow growth pattern responders. As reported in a previous work [14], we have favors clonal transformation; defects in DNA repair observed that among patients with advanced hyperparamechanisms may play a role [20] . Mendes et al [5] first thyroidism, a high set point is only observed in patients described frequent nodular formations in parathyroid with high PTH and elevated serum calcium, which sugglands from uremic patients with severe secondary hygests that the PTH is driving the serum calcium; these perparathyroidism. Nodular formation was observed in patients are not likely to respond to calcitriol therapy.
50% of glands weighing between 0.25 and 0.5 g parathy-The abnormal parathyroid response to calcitriol in roid and in more than 90% of glands weighing more than 0.5 g [21] . Nodules are formed by a greater proportion of uremic patients with severe parathyroid hyperplasia may Before calcitriol treatment, the mean basal/ maximal PTH ratio was similar in the Responders (A) and Non-Responders (B). In both groups, a similar shift to the right of the PTHcalcium curve was observed during calcitriol treatment with sustained increases in the serum calcium concentration. However, only in the Responders was the rightward shift in the PTH-calcium curve associated with a decrease in the mean basal/maximal PTH ratio. In C and D, the absolute values for basal, maximal, and minimal PTH are shown. Before calcitriol treatment, the basal and maximal PTH levels were less in the Responders (C) than the Non-Responders (D), and minimal PTH was not different. With calcitriol treatment basal, maximal, and minimal PTH values decreased in the Responders (C), but were essentially unchanged in the Non-Responders (D).
actively replicating cells [22] [23] [24] [25] . Nodular hyperplasia gene, have been found in only 10% of the patients [31, 32] and allelic loss of the Ha-ras gene and the tumor suppres-was also associated with a greater resistance to medical suppression of PTH oversecretion [24, 25] , and recur-sor gene WT1 in approximately 10% of the patients [33] . The expression of calcium sensor receptor and vitamin D rence rates of hyperparathyroidism after PTX were significantly higher when nodular tissue instead of purely receptor are decreased in nodular hyperplasia, however, mutations of these two important receptors have not hyperplastic tissue was autografted [26] .
been identified [29] . Several authors have shown, using X chromosome inactivation analysis, that benign monoclonal tumors are present in a large proportion of hyperplastic glands DIFFUSE HYPERPLASIA [27] [28] [29] and there was no correlation between clonal development and morphology [27] . Clonal development
The nodular hyperplasia of the parathyroids occurs at may be caused by mutations or losses of tumor suppresa late stage in the evolution of secondary hyperparathysor genes or activation of tumor enhancer genes [29, 30] .
roidism. During earlier stages of secondary hyperparathyroidism, parathyroid growth is polyclonal. The factors Losses on chromosome 11, the location of the menin S-158 ism [39, 40], other authors have not observed such association [41] [42] [43] .
Accumulation of phosphate is a key factor in the pathogenesis of hyperparathyroidism secondary to renal failure. High phosphate stimulates PTH secretion as demonstrated by in vivo and in vitro studies [44] [45] [46] [47] . In addition, animal studies strongly suggest that phosphate increases parathyroid cell proliferation [34, 48-50], however, possible mechanisms are not clear. In a recent work, Brown et al [51] clearly demonstrated that in renal failure rats fed a high phosphorus diet, the resulting parathyroid hyperplasia was associated with a decrease in calcium sensing receptor (CaR). This decrease in calcium sensing receptor may have been a direct effect of phosphate or a consequence of parathyroid gland hyperplasia. In a There are genes potentially involved in uremic hyperparathyroidism. In uremic rats the increase in parathyroid cell proliferation is associated with increased c-myc involved in the development of polyclonal parathyroid expression [38] . Acidic fibroblast growth factor autocrine hyperplasia appear to be the same factors that stimulate system has been proposed as a mediator of calcium-PTH secretion and synthesis: hypocalcemia, hyperphosregulated parathyroid cell growth in a clonal cell model [54] . In hyperplastic human parathyroid glands, proliferphatemia, and low serum calcitriol levels. The precise ating cells have a low expression of PTHrP [55] and mechanism by which each of these factors stimulates an increased expression of TGF-␣. [56] . Changes in the parathyroid cell proliferation is unknown.
expression of all these genes may be the consequence In rats on a low calcium diet with or without renal failrather that the cause of parathyroid hyperplasia. ure, there is a marked increase in parathyroid cell proliferation [34] . This effect is enhanced if rats have vitamin ACKNOWLEDGMENTS D deficiency. The importance of calcium on parathyroid cell proliferation is also demonstrated by the fact that in This work was in part supported by grants PB93-0720 and PM98-0184 from Ministry of Education, PB99-0768 from Ministry of Health, uremic rats the administration of calcimimetics prevent Fundació n Reina Sofía-Cajasur, and the "Consejeria de Salud de la parathyroid cell proliferation [35] . citriol did not reverse the parathyroid gland hyperplasia. 74:2136-2143, 1984 In vitro and in vivo studies [37, 38] indicates that calcitriol 
